Aptevo Therapeutics (NASDAQ:APVO) Trading Down 7.1% – Time to Sell?

Aptevo Therapeutics Inc. (NASDAQ:APVO)’s share price traded down 7.1% during mid-day trading on Tuesday . The stock traded as low as $4.38 and last traded at $4.42. 26,537 shares traded hands during trading, a decline of 73% from the average session volume of 96,504 shares. The stock had previously closed at $4.76.

Wall Street Analyst Weigh In

APVO has been the subject of a number of research reports. Wall Street Zen upgraded shares of Aptevo Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, March 29th. Weiss Ratings cut shares of Aptevo Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research note on Wednesday, July 1st. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold”.

Aptevo Therapeutics Stock Performance

The firm has a fifty day simple moving average of $4.68 and a two-hundred day simple moving average of $5.71. The firm has a market cap of $5.53 million, a PE ratio of -0.02 and a beta of 1.66.

Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($6.41) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($6.41). Equities analysts forecast that Aptevo Therapeutics Inc. will post -23.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new stake in Aptevo Therapeutics stock. Virtu Financial LLC bought a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned approximately 1.16% of Aptevo Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.